Home
Diseases
Glioblastoma

Glioblastoma

Disease

Disease Profile

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults, with rapid progression and poor overall prognosis. Clinical manifestations vary by tumor location and include headache, seizures, neurologic deficits, and cognitive changes. Standard treatment generally combines surgery, radiotherapy, and temozolomide-based chemotherapy.

Category: Primary malignant brain tumor
Prevalence: Incidence is approximately 3 per 100,000 people per year

ICD Codes

C71.9

Related News

Global Oncology and Radiopharmaceuticals Markets Poised for Strong Growth Through 2035

Jun 11, 2026

The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.

Long-Acting IL-7 and Oncolytic Virus Combo Improves Glioblastoma Immunotherapy in Mouse Study

Jun 08, 2026

A new "expand and pull" treatment strategy combines long-acting interleukin-7 and oncolytic virus therapy to boost T cell response in glioblastoma. In mouse models, the combination improved cytotoxic T cell function and led to long-term tumor-free survival.

BioNTech, BioLineRx Unveil Clinical Data at ASCO 2026

May 31, 2026

BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.

Viral Immunotherapy Studies Show Immune Activation in Glioblastoma

May 20, 2026

A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.

NR2F6 deletion boosts CAR-T activity against solid tumors

Apr 23, 2026

Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.

Wafik S. El-Deiry Highlights p53 Research and ONC201 Approval at Cancer Events

Apr 21, 2026

Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.

Tango Therapeutics plans pivotal vopimetostat trial in second-line pancreatic cancer

Apr 19, 2026

Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.

Champions Oncology to Present Eight Studies at AACR 2026

Apr 10, 2026

Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.

Combined Laser Therapy and Immunotherapy Shows Promise for Aggressive Brain Cancer

Mar 24, 2026

A clinical trial combining laser interstitial thermal therapy with pembrolizumab immunotherapy showed nearly half of recurrent high-grade astrocytoma patients alive at 18 months, far exceeding typical survival. Separate research reveals steroids make glioblastoma cells vulnerable to dietary interventions targeting their altered metabolism.

Researchers Develop New Immunotherapy Approaches for Cancer Treatment

Mar 22, 2026

Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07604285	A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07568782	Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.	NOT_YET_RECRUITING
NCT07560865	First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma	RECRUITING	PHASE1
NCT07552467	Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors	RECRUITING
NCT07551336	Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma	RECRUITING	PHASE1
NCT07541781	Sitagliptin in Recurrent/Progressive Grade 4 Glioma	NOT_YET_RECRUITING	PHASE1
NCT07532031	APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas	NOT_YET_RECRUITING
NCT07515924	Oral Gallium Maltolate for Recurrent Glioblastoma	NOT_YET_RECRUITING	EARLY_PHASE1
NCT07499141	Use of Fluorescence in Gliomas	COMPLETED
NCT07493447	Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures	NOT_YET_RECRUITING	EARLY_PHASE1